The course covers topics such as Introduction to the antimicrobial chemotherapeutics, Beta Lactam antibiotics, Vancomycin and other antimicrobial drugs, Macrolids, Quinolones, Sulfonamides, chloramphenicol and tetracyclines, Aminoglycosides, Antimycobacterial drugs, Antiviral drugs, Antiprotozoal drugs, Antifungal drugs, Antimalarial drugs, Antihelmintic drugs, Antiseptics and disinfectants, Pharmacology Of Renin Angiotensin System, Calcium Channel Blockers, Pharmacological Approach to Ischemic Heart Disease, Drugs Effecting Body Fluids & Volume, Anti-hypertensive Drugs, Hypolipidemic Drugs, Pharmacological Approach to Congestive Heart Disease, Antiarrhythmic Drugs, Bronchodilator Drugs, Antitussives, expectorants and surfactants, Antiplatelet Drugs, Antithrombotic and Thrombolytic drugs, Pharmacology and toxicology of tobacco, Prescription writing, Pharmacological basis of cancer therapy, Antineoplastic drugs.
Vertical Tabs
Course Learning Outcomes
|
Learning Outcomes
By the end of the course, the student should; |
Programme learning outcomes | Teaching Methods | Assessment Methods |
|
describe the concept of selective toxicity
describe the effects and mechanisms of action of a range of antibacterial and antiviral drugs. list the problems associated with using chemotherapeutic agents, especially the risk of toxicity and resistance. |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Beta Lactam antibiotics.
describe the mechanisms of action of this antibiotic group list the sub groups and members of this antibiotic group list the antimicrobial spectrum list the clinical uses describe the problems associated with this antibiotic group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Vancomycin and other antimicrobial drugs.
describe the mechanisms of action of this antibiotic group list the sub groups and members of this antibiotic group list the antimicrobial spectrum list the clinical uses describe the problems associated with this antibiotic group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Macrolids.
describe the mechanisms of action of this antibiotic group list the sub groups and members of this antibiotic group list the antimicrobial spectrum list the clinical uses describe the problems associated with this antibiotic group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Quinolones.
describe the mechanisms of action of this antibiotic group list the sub groups and members of this antibiotic group list the antimicrobial spectrum list the clinical uses describe the problems associated with this antibiotic group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Sulfonamides, chloramphenicol and tetracyclins.
describe the mechanisms of action of each antibiotic group list the sub groups and members of this antibiotic group list the antimicrobial spectrum list the clinical uses describe the problems associated with each antibiotic group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Aminoglycosides.
describe the mechanisms of action of this antibiotic group list the sub groups and members of this antibiotic group list the antimicrobial spectrum list the clinical uses describe the problems associated with this antibiotic group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antimycobacterial drugs.
describe the mechanisms of action of this antibiotic group list the sub groups and members of this antibiotic group list the antimicrobial spectrum list the clinical uses describe the problems associated with this antibiotic group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antiviral drugs.
describe the mechanisms of action of this group list the sub groups and members of this group list the antimicrobial spectrum list the clinical uses describe the problems associated with this group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antiprotozoal drugs.
describe the mechanisms of action of this group list the sub groups and members of this group list the antimicrobial spectrum list the clinical uses describe the problems associated with this group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antifungal drugs.
describe the mechanisms of action of this group. list the sub groups and members of this group list the antimicrobial spectrum list the clinical uses describe the problems associated with this group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antimalarial drugs.
describe the mechanisms of action of this group list the sub groups and members of this group list the antimicrobial spectrum list the clinical uses describe the problems associated with this group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antihelmintic drugs.
describe the mechanisms of action of this group list the sub groups and members of this group list the antimicrobial spectrum list the clinical uses describe the problems associated with this group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antiseptics and disinfectants.
describe the mechanisms of action of this group list the sub groups and members of this group list the antimicrobial spectrum list the clinical uses describe the problems associated with this group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Pharmacology Of Renin Angiotensin System.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Calcium Channel Blockers.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Pharmacological Approach to Ischemic Heart Disease.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Drugs Effecting Body Fluids & Volume.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Anti-hypertensive Drugs.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Hypolipidemic Drugs.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Pharmacological Approach to Congestive Heart Disease.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antiarrhythmic Drugs.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Bronchodilator Drugs.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antitussives, expectorants and surfactants.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antiplatelet Drugs.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antithrombotic and Thrombolytic drugs.
describe the basic physiology and pathophysiology describe the mechanisms of action of the drugs in this group list the sub groups and members of the drugs in this group list the clinical uses the drugs in this group describe the problems associated with this group related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Pharmacology and toxicology of tobacco.
describe the basic physiology and pathophysiology list the basic bioactive substances in tobacco describe the mechanisms of action of the basic bioactive substances in tobacco describe the problems associated with the bioactive substances related to toxicity |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Prescription writing.
describe the structure and the sections of the prescription describe the terms including original drug, equivalent drug, brand name and genericname write a complete prescription list the factors to be considered while writing a prescription |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Pharmacological basis of cancer therapy.
describe the basic properties of cancer describe the concepts of selective toxicity and log-‐kill hypothesis in cancer therapy list the effects and mechanisms of action of a range of anticancer drugs list the problems associated with using chemotherapeutic agents, especially the risk of toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
|
Antineoplastic drugs.
describe the mechanisms of action of antineoplastic drugs list the sub groups and members list the clinical uses describe the problems associated with this group related to toxicity and resistance |
PLO 9,15 | 1, 2, 3, 4, | A, B |
Course Flow
THEORETICAL COURSE CONTENT *FALL
| COURSE CONTENT (5th .semester) | |||
| Week | Theoretical Topics | Study Materials | |
| 1 | Introduction to the antimicrobial chemotherapeutics | Recommended resources | |
| 2 | Beta Lactam antibiotics | Recommended resources | |
| 3 | Vancomycin and other antimicrobial drugs | Recommended resources | |
| 4 | Macrolids, Quinolones, Sulfonamides | Recommended resources | |
| 5 | chloramphenicol and tetracyclines, Aminoglycosides | Recommended resources | |
| 6 | Antimycobacterial drugs, Antiviral drugs | Recommended resources | |
| 7 | Antiprotozoal drugs, Antifungal drugs | Recommended resources | |
| 8 | Antimalarial drugs, Antihelmintic drugs | Recommended resources | |
| 9 | Antiseptics and disinfectants | Recommended resources | |
| 10 | Pharmacology Of Renin Angiotensin System | Recommended resources | |
| 11 | Calcium Channel Blockers | Recommended resources | |
| 12 | Pharmacological Approach to Ischemic Heart Disease | Recommended resources | |
| 13 | Drugs Effecting Body Fluids & Volume | Recommended resources | |
| 14 | General review | Recommended resources | |
PRACTICAL COURSE CONTENT * FALL
| COURSE CONTENT (5th. semester) | |||
| Week | Practical Topics | Study Materials | |
| 1 | Lab studies | Study the sources. | |
| 2 | Lab studies | Study the sources. | |
| 3 | Lab studies | Study the sources. | |
| 4 | Lab studies | Study the sources. | |
| 5 | Lab studies | Study the sources. | |
| 6 | Lab studies | Study the sources. | |
| 7 | Lab studies | Study the sources. | |
| 8 | Lab studies | Study the sources. | |
| 9 | Lab studies | Study the sources. | |
| 10 | Lab studies | Study the sources. | |
| 11 | Lab studies | Study the sources. | |
| 12 | Lab studies | Study the sources. | |
| 13 | Lab studies | Study the sources. | |
| 14 | Lab studies | Study the sources. | |
Recommended Sources
| RECOMMENDED SOURCES | |
| Textbook |
1.John A. Yagiela, John A. Yagiela, Enid A. Neidle, Frank J. Dowd eds., Pharmacology and Therapeutics for Dentistry. Elsevier, Mosby. 6th ed. 2011.
B. G. Katzung: Basic and Clinical Pharmacology, 11th ed. McGraw-‐Hill Companies, New York, 2009. 2.Goodman&Gilman’s The Pharmacologic Basis of Therapeutics, 12th ed.McGraw Hill Medical, 2011
|
| Additional Resources |
- Lecture notes
|
Material Sharing
| MATERIAL SHARING | |
| Documents | Photocopy shareable. |
| Assignments | Sharable. |
| Exams | Not shareable. |
Assessment
| ASSESSMENT | ||
| IN-TERM STUDIES | NUMBER | PERCENTAGE |
| Midterm Exam | 1 | 50 |
| Quiz | - | - |
| Homework | - | - |
| Total | 50 | |
| CONTRIBUTION OF FINAL EXAMINATION TO OVERALL GRADE | 50 | |
| CONTRIBUTION OF IN-TERM STUDIES TO OVERALL GRADE | 50 | |
| Total | 100 | |
Course’s Contribution to Program
| COURSE'S CONTRIBUTION TO PROGRAM | |||||||
| No | Program Learning Outcomes | Contribution | |||||
| 1 | 2 | 3 | 4 | 5 | |||
| 9 | Integrating basic medical sciences in clinical sciences and using this information in all procedures of the patient. | X | |||||
| 15 | Following international literature, evaluating publications critically and integration of research results and evidence based dentistry during practice. | X | |||||
ECTS
| Activity | NUMBER |
Duration (Hours ) |
Total workload (Hours ) |
| Course duration 1st semester ( theoretical) | 14 | 2 | 28 |
| Course duration 2nd semester ( theoretical) | 14 | 2 | 28 |
| Course duration 1st semester ( practical ) | 14 | 1 | 14 |
| Course duration 2nd semester ( practical ) | 14 | 1 | 14 |
| Studies outside the class ( 1st semester ) | 14 | 4.5 | 63 |
| TOTAL | 147 | ||
| Total workload /25 | 5.8 | ||
| ECTS credits of the course | 6 |